NCT07050043View on ClinicalTrials.gov

Low Dose Nivolumab With Chemotherapy vs Standard Chemotherapy as First-Line Treatment in Advanced or Metastatic NSCLC

PHASE3RecruitingINTERVENTIONAL
Enrollment

123

Participants

Timeline

Start Date

May 19, 2025

Primary Completion Date

December 31, 2030

Study Completion Date

December 31, 2030

Conditions
NSCLC (Non-small Cell Lung Carcinoma)First Line TherapyLocally Advanced/Metastatic NSCLC
Interventions
DRUG

Nivolumab 40mg

Nivolumab is an immunotherapy medicine used to treat several cancers, including lung cancer.

DRUG

Cisplatin, Carboplatin, Pemetrexed, Gemcitabine, Paclitaxel, Docetaxel

Cisplatin, carboplatin, pemetrexed, paclitaxel, Gemcitabine, and docetaxel are chemotherapy drugs used to treat various types of cancer, including non-small cell lung cancer.

Trial Locations (1)

05460

RECRUITING

Hospital Sultanah Bahiyah, Alor Star

All Listed Sponsors
lead

Dr Arvindran A/L Alaga

OTHER_GOV